Longwood Fund
Venture capitalBoston · Seed–Series B · 47 people tracked
Also known as LONGWOOD MANAGEMENT LLC
Investment thesis
Longwood Fund focuses on creating and investing in novel healthcare and biotech companies that develop important treatments for patients. The firm acts as company co-founders and value-add investors, partnering with entrepreneurs, scientists, and academic innovators to turn groundbreaking discoveries into companies. It leverages its own company creation and operating experience to build businesses that both benefit patients and generate significant investor value. Its partners have founded over 20 biotech companies, which have launched roughly 25 drugs.
Source: firm website, verified Aug 25, 2026.
Team · 47 people
from the firm's website & curated & public directories
Founder mafia
4 people who came through Longwood Fund went on to found or lead other companies.
+ 2 more
What they invest in
from 45 of 71 portfolio companiesBiotech ×37Healthtech ×26Medical Devices ×16AI & Machine Learning ×4Deep Tech ×4Digital Health ×3Consumer ×2Direct to Consumer ×1
HQs:United States×31Canada×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×72 founders×33 founders×24+ founders×2
Investments · 71 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 52023 · 12022 · 22021 · 32020 · 12019 · 22018 · 12017 · 12015 · 12014 · 122 dated
BiotechCambridge, US
JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatShaan C. Gandhi· per SEC Form D · filed Oct 2021
Co-investors5AM VenturesAndreessen HorowitzPolaris Partners
HealthtechBoston, US
John Flavin(Director)Lucio Iannone(Director)
BoardGeeta Vemuri(Director)Jak Knowles(Director)
Board seatDavid SteinbergChristoph Westphal· per SEC Form D
Co-investorsRA CapitalAgent Capital
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+8 more
BiotechSouth Plainfield, US
Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)Marcio Souza(Executive Officer)Neil Almstead(Executive Officer)
Co-investorsBay City Capital
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesOberland CapitalOrbiMed
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)Edward Holson(Co-founder & CSO)Lizzie Ngo(Co-founder)Brian Fenton(President & CEO)
Co-investorsMPM BioImpact8VCMRL Ventures FundOno Venture Investment, Inc.
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsOxford Science EnterprisesSofinnova PartnersSV Health Investors
HealthtechLowell, US
PJ Anand(Executive Officer, Director)
BoardEdgar D. Jannotta(Director)Edgar Jannotta, Jr.(Director)Norbert Riedel(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $31.6M raise · filed Jan 2025
Anuncia Medical develops the ReFlow Ventricular System, an implantable device that lets patients or caregivers non-invasively flush a shunt catheter to help manage hydrocephalus, including in pediatric patients.
BiotechHealthtechMedical DevicesScottsdale, US
Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)
BoardEdgar D Janotta(Director)Stanton Rowe(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
Co-investorsXcellerant Ventures
HealthtechLexington, US
Barbara S. Fox(Executive Officer, Director)Eileen F. Bostwick(Executive Officer)David C. Dlesk(Executive Officer)David Poorvin(Executive Officer, Director)
BoardJonathan Fleming(Director)
Board seatDavid Donabedian· per SEC Form D · $5M raise · filed Jul 2015
Co-investorsBoston Harbor AngelsKeiretsu Forum
BiotechBoston, US
SARKIS K. MAZMANIAN(Director)DAVID H. DONABEDIAN(CHIEF EXECUTIVE OFFICER OF THE ISSUER)Ronald C. Renaud Jr.(Director)Henry Wolf(Director)
BoardJAMES C. BLAIR(Director)MICHELLE DIPP(Director)
Board seatRichard P. Aldrich· per SEC Form D · $28M raise · filed Nov 2018
Co-investorsDomain Partners
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingBoston, US
Board seatDavid Steinberg· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Agent Capital
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)Theodore Ebel(Executive Officer)Lynelle Lynch(Director)Howard D. Palefsky(Director)Brian H. Dovey(Director)
Board seatRichard Aldrich· per SEC Form D
Co-investors1315 CapitalAisling CapitalDomain AssociatesHealthCare Ventures, LLCRoundTable Healthcare PartnersSplit Rock Partners
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDC Investment PartnersMedical Excellence CapitalNovartis Venture FundOno Venture Investment, Inc.Solasta VenturesAgent Capital+2 more
HealthtechLunenburg, US
PJ Anand(Executive Officer, Director)
BoardRichard Upton(Director)Edgar D. Jannotta Jr.(Director)Norbert Riedel(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $21.5M raise · filed May 2026
BiotechBoston, US
David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardMing Cheah(Director)Raymond Camahort(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDCVC (Data Collective)DCVC BioNovo Holdings
Boston, US
Jim O'Connor(Executive Officer)Eileen Maus(Executive Officer, Director)
BoardTara Butler(Director)Adam Stone(Director)Dan Levangie(Director)
Board seatRich Aldrich· per SEC Form D · $19.1M raise · filed Apr 2021
Co-investorsAscension Ventures
A company focused on developing clinical treatments aimed at improving patient outcomes.
BiotechHealthtechMedical DevicesBoston, US
David Southwell(Executive Officer, Director)Robert Crane(Executive Officer)
BoardSteve Kraus(Director)inCampbell Murray(Director)Hannes Smarason(Director)in
Board seatChristoph WestphalLea Hachigian· per SEC Form D
Co-investorsAstellas Venture Management LLCBessemer Venture PartnersRA Capital6 Dimensions CapitalLongwood Special SituationsPitango
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatShaan C. Gandhi· per SEC Form D · $75M raise · filed Aug 2022
Co-investorsAtlas VentureLightstone VenturesVida VenturesHatteras Venture Partners
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesMPM BioImpactRA CapitalTaiho Ventures, LLC
Clinical-stage gene therapy company developing AAV therapeutics for inherited retinal disorders.
Co-investorsSixty Degree CapitalXGEN Venture
Co-investorsAtlas Venture
Neomorph develops molecular glue degraders designed to target and degrade disease-causing proteins through engineered neomorphic protein surfaces.
BiotechDeep Tech
Co-investorsDeerfield Management Company
Co-investorsFrazier Life Sciences
HealthtechBoulder, US
Jason Myers(Executive Officer, Director)Christian LaPointe(Executive Officer)
BoardKyle Lefkoff(Director)inPaul Manning(Director)in
Co-investorsCrawley VenturesBoulder VenturesPBM Capital
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsDelos CapitalForesite CapitalINCE CapitalNew Enterprise Associates (NEA)OrbiMedQuan Capital+3 more
Restaurant tech company; $100M exit.
Co-investorsAnalog VenturesBranded Strategic HospitalityFour Acres CapitalGV (Google Ventures)Rally Ventures Management, LlcSupernode Ventures+2 more
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersNextech InvestPathway to CuresAtlas Venture+6 more
Co-investorsAlta Partners
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)NIGEL CROCKETT(Executive Officer)NICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)MICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalSR One Capital ManagementSV Health InvestorsVertex Ventures HC
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSSequoia Capital
Co-investorsMission Bay CapitalMission Biocapital
BiotechSouth San Francisco, US
Susan M. Molineaux(Executive Officer, Director)Jean M. George(Director)William Waddill(Executive Officer)Deepa Pakianathan(Director)Jonathan Drachman(Director)Ralph E. Christoffersen(Director)
Co-investorsVenture Capital Investment Management
HealthtechEmeryville, US
Daniel Burnett(Director)Ulric Cote(Executive Officer, Director)Carter Meyer(Director)Bill Malecki(Executive Officer)
BoardDr. Jason Hong(Director)Anthony Natale(Director)in
Co-investorsAPERTURE Venture PartnersGreen Park & Golf VenturesScientific Health DevelopmentThird Point VenturesVHM
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
Co-investorsSofinnova VenturesBAM ElevateFinchley Healthcare VenturesForbionLuma GroupNovo Holdings+1 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersFrazier Life SciencesLightstone Ventures
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(Executive Officer, Director)Janice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+2 more
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersEcoR1 CapitalLightstone Ventures
IlluminOss Medical makes a light-curable, patient-conforming intramedullary implant for minimally invasive fracture repair.
Co-investorsExcel Venture ManagementSlater Technology Fund
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE).
BiotechHealthtech
Co-investorsFrazier Life SciencesRA Capital
Co-investorsFrazier Life SciencesSV Health Investors
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestAlexandriaLilly Asia Ventures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalBiotechnology Value FundCatalio Capital Management+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLCSofinnova Partners+2 more
Co-investors5AM Ventures
Co-investorsOUP (Osage University Partners)
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersMission BiocapitalDolby Family VenturesForbionService Provider Capital
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)Kazuhiro Ito(Co-founder)John Murray(Co-founder)David Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalSR One Capital ManagementSV Health InvestorsVivo Capital+1 more
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)Robert Hughes(Chief Scientific Officer)Pol Boudes(Chief Medical Officer)
Co-investorsAtlas VentureDC Investment Partners
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)
Co-investorsAstellas Venture Management LLCFrazier Life SciencesNovartis Venture FundOrbiMedInsight Partners
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels.
BiotechHealthtech
Phil Vickers(CEO / Leadership)Michael Boretti(Leadership)Brandon Turunen(Leadership)Sergio Santillana(Leadership)Enda Moran(Leadership)Kelly Honohan(Leadership)
Co-investorsAstellas Venture Management LLCPappas Capital
Co-investorsDC Investment PartnersPfizer Venture InvestmentsQuan CapitalAgent Capital
Pyxis Oncology develops clinical-stage cancer therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, aimed at difficult-to-treat cancers.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsAgent Capital
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)
Co-investorsARCH Venture PartnersBreyer CapitalF-Prime CapitalForesite CapitalMenlo VenturesNew Enterprise Associates (NEA)+1 more
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)James Cohen(Director)
Co-investorsLumira VenturesFountain Healthcare PartnersJeito CapitalSofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
IPOs and acquisitions across the tracked portfolioCamp4 Therapeutics CorpNASDAQ: CAMPPyxis OncologyNASDAQ: PYXSGRAILNASDAQ: GRALPtc TherapeuticsNASDAQ: PTCTVerastemNASDAQ: VSTM
Portfolio news
latest coverage across their companiesPyxis Oncology · scanx.trade · Aug 20, 2026
Khartis Therapeutics · allsci.com · Aug 14, 2026
Bicycle · ocregister.com · Aug 11, 2026
Evommune · stocktitan.net · Aug 6, 2026
Sidewinderbio · techcrunch.com · Jul 30, 2026
GRAIL · simplywall.st · Jul 17, 2026
Xaira Therapeutics · thenextweb.com · Jul 15, 2026
Frequently asked questions
- How many investments has Longwood Fund made?
- Longwood Fund has 54 tracked investments, 1 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does Longwood Fund invest at?
- Longwood Fund invests at the Seed, Series A, Series B stages.
- What sectors does Longwood Fund focus on?
- Longwood Fund focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Longwood Fund located?
- Longwood Fund is headquartered in Boston, US.
- Does Longwood Fund lead rounds?
- Longwood Fund typically participates in rounds rather than leading them.
- Who does Longwood Fund co-invest with?
- Longwood Fund most often shares deals with DC Investment Partners, Frazier Life Sciences, Alta Partners, among 89 tracked co-investors.
Images
Co-investors · 15
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
▶3 more co-investors
Longitude CapitalWestlake Village BioPartnersDe Novo Ventures
Firms observed investing alongside Longwood Fund, from public investor directories. Shared companies are the overlap with Longwood Fund's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.